Dr. Johann S. de Bono, MD Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Description: Results from a pre-specified interim analysis of a randomized, placebo controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo. This study included 1,195 patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer, or CRPC) previously treated with one or two chemotherapy regimens, at least one of which contained docetaxel.
Treatment with abiraterone acetate resulted in a 35 percent reduction in the risk of death
(HR=0.65; 95 percent CI: 0.54, 0.77; p<0.0001) and a 36 percent increase in median survival
(14.8 months vs. 10.9 months) compared with placebo.